Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:896467.
doi: 10.1155/2013/896467. Epub 2013 May 8.

The effects of xuefu zhuyu and shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after percutaneous coronary intervention: a randomised controlled clinical trial

Jie Wang  1 , Xiaochen Yang, Fuyong Chu, Jianxin Chen, Qingyong He, Kuiwu Yao, Fei Teng, Yonghong Gao, Yanhui Xing, Aiming Wu, Yanwei Xing
Affiliations

The effects of xuefu zhuyu and shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after percutaneous coronary intervention: a randomised controlled clinical trial

Jie Wang et al. Evid Based Complement Alternat Med. 2013.

Abstract

We evaluated the effects of the Xuefu Zhuyu capsule (XFZY) and the Shengmai capsule (SM) on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris (UAP) after percutaneous coronary intervention (PCI). Ninety patients with UAP after PCI were randomly and equally assigned to three groups: the XFZY group, the SM group, and the placebo group, with 30 patients in each group. Six syndrome factors (including Qi deficiency, yin deficiency, yang deficiency, blood stasis, phlegm, and Qi stagnation) and 4 inflammatory markers (high-sensitivity C-reactive protein (Hs-CRP), endothelins-1 (ET-1), matrix metalloproteinases-9 (MMP-9), and homocysteine (Hcy)) were observed at week 0 and at the 1st, 4th and 12th weeks. In conclusion, the evolution of syndromes present in patients with UAP after PCI followed these trends (1) The deficiency syndromes gradually increased during a 12-week period, but the excess syndromes first gradually decreased and then mildly increased after PCI. (2) XFZY and SM can prevent excess syndromes from increasing in the later stages and prevent deficiency syndromes from increasing in all stages. (3) XFZY and SMcan reduce the levels of the inflammatory markers, especially in the later stages after PCI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Participant recruitment, allocation, followup, and analysis.
Figure 2
Figure 2
Effects of XFZY and SM on the evolution of syndrome factors in the patient with unstable angina pectoris. (a1) Effects of XFZY and SM on the Qi deficiency syndrome. (a2) Effects of XFZY and SM on the yin deficiency syndrome. (a3) Effects of XFZY and SM on the yang deficiency syndrome. (b1) Effects of XFZY and SM on the blood stasis syndrome. (b2) Effects of XFZY and SM on the phlegm syndrome. (b3) Effects of XFZY and SM on the Qi stagnation syndrome; (★ P < 0.05 versus the control group at the same time; ◆ P < 0.05 versus before treatment in the same group. ▲ P < 0.05, XFZY group versus SM group at the same time).
Figure 3
Figure 3
Effects of XFZY and SM on Hs-CRP, ET-1, MMP-9 and Hcy. (a) Effects of XFZY and SM on Hs-CRP. (b) Effects of XFZY and SM on ET-1. (c) Effects of XFZY and SM on MMP-9. (d) Effects of XFZY and SM on Hcy; (★ P < 0.05 versus the control group at the same time; ◆ P < 0.05 versus before treatment in the same group; ▲ P < 0.05, XFZY group versus SM group at the same time).
See this image and copyright information in PMC

References

    1. Yangfeng W. Current status of major cardiovascular risk factors in Chinese populations and their trends in the past two decades. Chinese Journal of Cardiology. 2001;29(2):74–79.
    1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation. 2008;117(4):e25–e146. - PubMed
    1. Grech ED. ABC of interventional cardiology: percutaneous coronary intervention. II: the procedure. British Medical Journal. 2003;326(7399):1137–1140. - PMC - PubMed
    1. Ma X, Wu T, Robich MP, et al. Drug-eluting stents. International Journal of Clinical and Experimental Medicine ,2010;3(3):192–201. - PMC - PubMed
    1. Aziz S, Morris JL, Perry RA. Late stent thrombosis associated with coronary aneurysm formation after sirolimus-eluting stent implantation. Journal of Invasive Cardiology. 2007;19(4):E96–E98. - PubMed